SDGR vs RXRX
SDGR 与 RXRX 的估值与基本面并排对比(公开数据)。
关键统计
| 指标 | SDGRSchrodinger, Inc. | RXRXRECURSION PHARMACEUTICALS, INC. |
|---|---|---|
| 市值 | — | $2.05B |
| 市销率 | — | 27.5x |
| 营收 | $259.04M(TTM) | — |
| 营收同比增长 | 23.3% | 26.9% |
| 净利润 | -$54.34M(TTM) | — |
| 净利同比增长 | 44.8% | -39.1% |
| 每股收益(稀释) | $-0.73(TTM) | — |
| 息税前利润率 | -65.2% | -867.9% |
| 净资产收益率 | -31.4% | -70.5% |
| 投入资本回报率 | — | -175.2% |
| 一年总回报 | +47.6% | -22.2% |
数据来自 SEC 文件 · 仅供参考 · 非投资建议
1 万美元的成长:SDGR vs RXRX
| 指标 | SDGR | RXRX |
|---|---|---|
| 期末价值 | $3.7K | $1.2K |
| 总回报 | -62.8% | -87.8% |
| 年化收益 (CAGR) | -16.6% | -32.1% |
| 波动率 | 63.8% | 92.6% |
| 夏普比率 | -0.04 | -0.02 |
| 索提诺比率 | -0.06 | -0.04 |
| 最大回撤 | -86.0% | -93.1% |
基于 1363 个共同交易日,2021-04-16 → 2026-09-18 · 无风险利率 4.14%(当前短端国债,全程恒定)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
相关对比
数据延迟 · 公开数据 · 仅供参考 · 非投资建议(本页不评判孰优孰劣)